SCHEMBL4919975

SCHEMBL4919975

O=C(COc1cc(-c2nc3ccccc3[nH]2)[nH]n1)Nc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
KDM4E B2RXH2 4/20 0.62
ALDH1A1 P00352 4/20 0.62
LMNA P02545 4/20 0.62
MEN1 O00255 3/20 0.62
POLB P06746 3/20 0.62
KMT2A Q03164 3/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
TP53 P04637 4/20 0.56
NPC1 O15118 3/20 0.56
NPSR1 Q6W5P4 1/20 0.56
RAB9A P51151 2/20 0.52
ALOX12 P18054 1/20 0.52
HPGD P15428 2/20 0.52
GAA P10253 2/20 0.52
GLA P06280 1/20 0.52
HTT P42858 1/20 0.52
FOXO1 Q12778 2/20 0.50
MMP2 P08253 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915117 0.82 FOXO1 (0.49) MAPTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4922243 0.81 FOXO1 (0.48) MAPTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4923470 0.81 FOXO1 (0.48) MAPTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4920702 0.81 KDM4E (0.49) MAPTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4910663 0.80 FOXO1 (0.55) MAPTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4921877 0.79 FOXO1 (0.46) SMN1; SMN2KDM4EALDH1A1LMNATP53
SCHEMBL4920773 0.79 FOXO1 (0.46) MAPTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4923424 0.78 FOXO1 (0.52) MAPTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4910701 0.78 NPC1 (0.52) MAPTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL25429204 0.78 FOXO1 (0.64) FOXO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US claimed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US claimed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP claimed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US claimed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO claimed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-20080125418-A1 Benzimidazole derivatives and their use as kdr kinase protein inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-29 US disclosed
US-20080125418-A1 Benzimidazole derivatives and their use as kdr kinase protein inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-29 US disclosed
US-20080125418-A1 Benzimidazole derivatives and their use as kdr kinase protein inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-29 US disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
US-20050009894-A1 Benzimidazole derivatives and their use as KDR kinase protein inhibitors AVENTIS PHARMA S.A. (FR) 2005-01-13 US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 MAPT 3479/4885SMN1; SMN2 4210/4885KDM4E 522/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A MAPT 4186/4885SMN1; SMN2 3516/4885KDM4E 645/4885
US-20080125418-A1 Benzimidazole derivatives and their use as kdr kinase protein inhibitors KDR, MUSK, FLT4 MAPT 3744/4885SMN1; SMN2 1094/4885KDM4E 1025/4885
US-20050009894-A1 Benzimidazole derivatives and their use as KDR kinase protein inhibitors KDR, MUSK, FLT4 MAPT 3719/4885SMN1; SMN2 1091/4885KDM4E 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.